Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C14H19NO5 |
Molecular Weight | 281.3044 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]1([C@@H](C)O)C(=O)N2C(C(O)=O)=C3[C@H](CCC[C@]3([H])[C@]12[H])OC
InChI
InChIKey=ICFDDEJRXZSWTA-KJFVXYAMSA-N
InChI=1S/C14H19NO5/c1-6(16)9-11-7-4-3-5-8(20-2)10(7)12(14(18)19)15(11)13(9)17/h6-9,11,16H,3-5H2,1-2H3,(H,18,19)/t6-,7+,8+,9-,11-/m1/s1
Sanfetrinem cilexetil (formerly known as GV 118819), a beta-lactam antibiotic, is the oral prodrug of sanfetrinem. Experiments on rodents have revealed that sanfetrinem cilexetil had strong antibacterial activity in vitro and good pharmacokinetic behavior in mice. This drug was suitable for the treatment of infections caused by a variety of bacteria and participated in a phase II clinical trial. However, this study was discontinued.
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Automated assay for GV104326, a novel tribactam antibiotic, in human plasma by high-performance liquid chromatography and solid-phase extraction. | 1994 Feb 4 |
|
In vitro activity of the tribactam GV104326 against gram-positive, gram-negative, and anaerobic bacteria. | 1994 Oct |
|
In vitro activity of sanfetrinem (GV104326), a new trinem antimicrobial agent, versus Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. | 1996 Sep |
|
Sanfetrinem and sanfetrinem-cilexetil: disposition in rat and dog. | 1997 Jul |
|
In vivo antibacterial activities of sanfetrinem cilexetil, a new oral tricyclic antibiotic. | 1998 Jul |
|
In-vitro activity of sanfetrinem against isolates of Streptococcus pneumoniae and Staphylococcus aureus. | 1998 Nov |
|
Carboxylesterases, a key factor in evaluating potential genotoxicity of Trinem antibiotics. | 2000 Jan |
|
[Sanfetrinem, the member of trinems--in vitro activity against Klebsiella pneumoniae producing ESBL]. | 2006 |
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8950528
The activity of sanfetrinem was determined using a broth microdilution MIC method versus a large number of clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis obtained in a recent 30-center United States surveillance study. The sanfetrinem MIC50 and MIC90 values for these three organism groups were 0.015 and 0.5 microgram/ml, 0.25, and 0.5 microgram/ml, and 0.015 and 0.03, respectively.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C260
Created by
admin on Sat Dec 16 17:26:07 GMT 2023 , Edited by admin on Sat Dec 16 17:26:07 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CHEMBL316197
Created by
admin on Sat Dec 16 17:26:07 GMT 2023 , Edited by admin on Sat Dec 16 17:26:07 GMT 2023
|
PRIMARY | |||
|
7291
Created by
admin on Sat Dec 16 17:26:07 GMT 2023 , Edited by admin on Sat Dec 16 17:26:07 GMT 2023
|
PRIMARY | |||
|
C104757
Created by
admin on Sat Dec 16 17:26:07 GMT 2023 , Edited by admin on Sat Dec 16 17:26:07 GMT 2023
|
PRIMARY | |||
|
100000084052
Created by
admin on Sat Dec 16 17:26:07 GMT 2023 , Edited by admin on Sat Dec 16 17:26:07 GMT 2023
|
PRIMARY | |||
|
CHEMBL2107073
Created by
admin on Sat Dec 16 17:26:07 GMT 2023 , Edited by admin on Sat Dec 16 17:26:07 GMT 2023
|
PRIMARY | |||
|
156769-21-0
Created by
admin on Sat Dec 16 17:26:07 GMT 2023 , Edited by admin on Sat Dec 16 17:26:07 GMT 2023
|
PRIMARY | |||
|
C73825
Created by
admin on Sat Dec 16 17:26:07 GMT 2023 , Edited by admin on Sat Dec 16 17:26:07 GMT 2023
|
PRIMARY | |||
|
0S36458I44
Created by
admin on Sat Dec 16 17:26:07 GMT 2023 , Edited by admin on Sat Dec 16 17:26:07 GMT 2023
|
PRIMARY | |||
|
71452
Created by
admin on Sat Dec 16 17:26:07 GMT 2023 , Edited by admin on Sat Dec 16 17:26:07 GMT 2023
|
PRIMARY | |||
|
SUB10441MIG
Created by
admin on Sat Dec 16 17:26:07 GMT 2023 , Edited by admin on Sat Dec 16 17:26:07 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
PRODRUG (METABOLITE ACTIVE)
SALT/SOLVATE (PARENT)